Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study

Table 1 Changes of primary tumor in patients with renal cell carcinoma before and at 12 weeks after neoadjuvant therapy

Variable	Axitinib	Sunitinib	Sorafenib	P ¹	P ²	P ³
Maximal diameter (cm)^a
Before therapy	7.2 (6.2–8.5)	6.4 (5.7–10.3)	6.8 (5.8–11.0)	0.497	0.664	0.868
After therapy	5.2 (4.4–7.4)	5.6 (5.1–9.8)	6.4 (4.8–6.4)	0.266	0.284	0.657
Reduction	1.5 (1.2–2.2)	0.8 (0.5–1.1)	0.5 (0.4–0.8)	0.001	< 0.001	0.024
Reduction rate (%)^a	22.4 (13.8–30)	12.2 (7.1–14.1)	6.9 (3.7–12.0)	0.001	0.001	0.023
> 10% reduction [cases (%)]	13 (86.7)	16 (66.7)	8 (26.7)	0.310*	0.001*	0.003*

P¹, axitinib vs. sunitinib; P², axitinib vs. sorafenib; P³, sunitinib vs. sorafenib
P, Wilcoxon signed-rank test; P*, Pearson’s Chi square test
^aThe data are presented as median (interquartile range)